anti-Amyloid beta (Abeta) Antibodies

Abeta encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Additionally we are shipping beta Amyloid Proteins (3) and beta Amyloid Kits (2) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
Abeta 351 P05067
Abeta 54226 P08592
Abeta 11820 P12023
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-beta Amyloid Antibodies at

Showing 10 out of 258 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Mouse Un-conjugated ELISA, ICC, IF, IHC, IHC (ff), IHC (p), IP, WB Immunocytochemistry/Immunofluorescence: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - Immunofluorescent detection of beta Amyloid with MOAB-2 in the subiculim of 1-, 2- and 4- month old 5xFAD mice. Scale bar 20 um (from PMID: 22423893). Immunohistochemistry: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - IHC analysis of beta Amyloid on normal mouse brain (left) and 5xFAD mouse brain (right) using DAB with hematoxylin counterstain. The MOAB-2 antibody was used at 1:20 on normal mouse brain and at 1:400 on 5xFAD mouse brain. 0.1 mL Log in to see 7 to 9 Days
Human Rabbit Un-conjugated IHC, ELISA, WB 100 μg Log in to see 5 to 7 Days
Cow Rabbit Un-conjugated ELISA, ICC, IF, IHC, Act (ligand), WB Western Blot: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Lane 1-10: beta Amyloid pyro E3 peptide. Load: 1 ug per lane 1-2, 0.2 ug per lane 3-4, 0.05 ug per lane 5-6, 0.01 ug per lane 7-8, 0.005 ug per lane 9-10. Primary antibody: Beta Amyloid pyro E3 antibody at 0.5 ug/mL for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 86.9 kDa for beta Amyloid pyro E3 peptide. Cross reactivity with Beta Amyloid 3 peptide is >1000 fold below pyrE3 reactivity and contains no reactivity towards the Beta Amyloid 42 A beta peptide (data not shown). Immunocytochemistry/Immunofluorescence: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Laser scanning confocal microscopy was carried out using human tissue sections from frontal cortex. Figure A shows an example section that was immunostained for the presence of pyrE3Abeta (green). Figure B shows that the immunogen peptide completely blocked the NBP1-44048 antibody. 0.05 mg Log in to see 7 to 9 Days
Cow Rabbit Un-conjugated WB Western blot analysis of Beta Amyloid expression in HEK293T (A), Hela (B) whole cell lysates. 200 μL Log in to see 13 to 14 Days
Chicken Rabbit Un-conjugated IHC, WB Immunohistochemical analysis of Beta Amyloid (pT743) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. Western blot analysis of Beta Amyloid (pT743) expression in MCF7 colchicine-treated (A), mouse liver (B), PC12 (C) whole cell lysates. 200 μL Log in to see 13 to 14 Days
Human Mouse Un-conjugated ELISA, IF, WB Fluorescent microscopy image (appotome) of 6 months-old APP/PS1 mouse hypocampus and somatosensory cortex. Double staining: in blue, nuclei DAPI staining. In red, Amyloid plaques. Immunofluorescence slices with the anti-amyloid beta antibody from different mouse genotypes. Wild type (WT), APP/PS1 and APP KO. In red, amyloid plaques. 100 μg Log in to see 6 to 7 Days
Human Rabbit Un-conjugated WB Western blot analysis of Beta Amyloid expression in mouse kidney (A), mouse heart (B) whole cell lysates. 200 μL Log in to see 13 to 14 Days
Human Rabbit Un-conjugated EIA, IF, IHC (p), WB 0.1 mg Log in to see 6 to 8 Days
Human Rabbit Un-conjugated ELISA, IHC, IHC (p), WB Immunohistochemistry: beta Amyloid Antibody [NBP2-25093] - Analysis of APP in human brain tissue with APP antibody at 2.5 ug/ml. Immunohistochemistry-Paraffin: beta Amyloid Antibody [NBP2-25093] - Human brain (Alzheimer's disease) tissue with APP antibody at 10 ug/mL. 0.1 mg Log in to see 8 to 11 Days
Human Rabbit Un-conjugated ICC, IF, IHC (p), IHC, WB Western Blot: beta Amyloid Antibody [NBP1-32081] - Sample(30 ug of whole cell lysate)A:Hep G2 7. 5% SDS PAGE, antibody diluted at 1:1500. 0.1 mL Log in to see 8 to 11 Days

Top referenced anti-beta Amyloid Antibodies

  1. Human Monoclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284085 : Youmans, Tai, Kanekiyo, Stine, Michon, Nwabuisi-Heath, Manelli, Fu, Riordan, Eimer, Binder, Bu, Yu, Hartley, LaDu: Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. in Molecular neurodegeneration 2012 (PubMed)
    Show all 16 Pubmed References

  2. Cow (Bovine) Polyclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284076 : He, Barrow: The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. in Biochemistry 1999 (PubMed)
    Show all 4 Pubmed References

  3. Human Monoclonal beta Amyloid Primary Antibody for ELISA, IF - ABIN5508784 : Markoutsa, Papadia, Clemente, Flores, Antimisiaris: Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells. in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2012 (PubMed)
    Show all 4 Pubmed References

  4. Human beta Amyloid Primary Antibody for ELISA (Capture), IF - ABIN1110165 : Levites, Jansen, Smithson, Dakin, Holloway, Das, Golde et al.: Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor ... in The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 (PubMed)
    Show all 3 Pubmed References

  5. Fruit Fly (Drosophila melanogaster) Polyclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284077 : Youssef, Florent-Béchard, Malaplate-Armand, Koziel, Bihain, Olivier, Leininger-Muller, Kriem, Oster, Pillot: N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. in Neurobiology of aging 2008 (PubMed)
    Show all 3 Pubmed References

  6. Human beta Amyloid Primary Antibody for IF, IP - ABIN1110164 : Levites, Smithson, Price, Dakin, Yuan, Sierks, Kim, McGowan, Reed, Rosenberry, Das, Golde: Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006 (PubMed)
    Show all 2 Pubmed References

  7. Human beta Amyloid Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN1110166 : Levites, Das, Price, Rochette, Kostura, McGowan, Murphy, Golde: Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. in The Journal of clinical investigation 2006 (PubMed)
    Show all 2 Pubmed References

  8. Human Polyclonal beta Amyloid Primary Antibody for IHC (fro), IHC (p) - ABIN2477631 : Romaguera, Grimalt, Vilaplana: Eczematous and purpuric allergic contact dermatitis from boots. in Contact dermatitis 1990 (PubMed)
    Show all 3 Pubmed References

  9. Human Polyclonal beta Amyloid Primary Antibody for ELISA, WB - ABIN1573928 : Jia, Liu, Song, Pan, Chen, Cui, Wang: Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways. in The Journal of pharmacy and pharmacology 2012 (PubMed)

More Antibodies against beta Amyloid Interaction Partners

Human Amyloid beta (Abeta) interaction partners

  1. The neuronal specific alpha3 (alpha3)-subunit of the plasma membrane enzyme Na, K-ATPase (NKA) is a new binding partner of sAPPalpha.

  2. Aggregation processes of ABETA on living cells and cytotoxic events were monitored by fluorescence techniques. ABETA formed amyloids after forming oligomers composed of approximately 10 ABETA molecules. The formation of amyloids was necessary to activate apoptotic caspase-3 and reduce the ability of the cell to proliferate; this indicated that amyloid formation is a key event in ABETA-induced cytotoxicity.

  3. esults suggest that P-gp plays important role in mediating rivastigmine non-cholinergic beneficial effects, including Abeta brain load reduction, neuroprotective and anti-inflammatory effects in the AD mouse models.

  4. Immature intracellular aggregates are more toxic than mature fibrillar ABETA(1-42).

  5. Downregulation of C9orf72 in non-neuronal human cells overexpressing amyloid-beta protein precursor (AbetaPP) resulted in increased levels of secreted AbetaPP fragments and Abeta, while levels of AbetaPP or its C-terminal fragments (CTFs) remained unchanged. In neuronal cells, AbetaPP and C83 CTF levels were decreased upon C9orf72 knockdown, but those of secreted AbetaPP fragments or Abeta remained unchanged.

  6. N-terminal mutations can affect Abeta fibril and oligomer formation, despite lying outside the core amyloid region of Abeta. Of the three factors that may influence Abeta-mediated toxicity (primary structure of Abeta, assembly structure and cellular responses), results suggest that it is more the assembly structure that correlates with effects on cell viability.

  7. The Swedish variant was a more potent co-activator of Wnt-PCP signalling than wild-type APP and, unlike wild-type APP, which co-activates Wnt beta-catenin signalling, APPSwe suppressed this branch of Wnt.

  8. Among hip fracture patients, 88.6% of the cognitively normal (Clinical Dementia Rating-CDR 0; n = 70) and 98.8% with mild cognitive impairment (CDR 0.5; n = 81) fell in the abnormal biomarker categories by CSF Abeta42/40 ratio, p-tau, and t-tau measures.

  9. FNDC5 significantly affects beta-cleavage of APP via the interaction with APP.

  10. uncovered for the first time a phenomenon of chaperone antagonism on BACE1-mediated Abeta42 generation.

  11. This study investigated the assembly mechanisms of dimeric ABETA 16-22 and found that the fibril formation rate is predominantly controlled by the total beta-strand content.

  12. Data suggest that the substitution of alanine by valine at position 2 of the amyloidogenic peptide affect the lateral interactions between fibrils, promoting a more compact, aligned and uniform structure which explains its aggressiveness in homozygous carriers and its prophylactic effect in heterozygous carriers.

  13. Solution NMR allowed us to define the secondary structure of this Abeta dimer, which shows interlocking contacts between C-terminal peptide strands. Thus, we present a novel Abeta oligomer that resists conversion to fibrils and remains stable for more than one year.

  14. Data suggest that antiinflammatory agents, non steroidal (NSAIDs) bind to amyloid beta (Abeta) protein leading to the blockage of hydrophobic site which might prevent incoming Abeta molecules from extending the fibril.

  15. Findings suggest that the polymorphisms of amyloid-beta (Abeta) fibril structures are caused by differences in the surrounding ionic environment.

  16. Young healthy adults carrying APOE epsilon4 and APP/presenilin-1/2 displayed different hippocampus functional connectivity patterns

  17. X-box binding protein 1 overexpression at an early stage reversed Abeta-induced early death without affecting learning performance in the Abeta42 transgenic flies. PERK activation was determined to only enhance Abeta-induced learning deficits.

  18. data suggests that the hydrophobic interactions between beta-casein and Abeta1-42 play an important role in the burial of the hydrophobic part of the Abeta1-42.

  19. APP-Knockout astrocytes have reduced cholesterol and elevated levels of sterol regulatory element-binding protein (SREBP) target gene transcripts and proteins, which were both downstream consequences of reduced lipoprotein endocytosis.

  20. Identified TMEM30A as a candidate partner for beta-carboxyl-terminal fragment (betaCTF) of amyloid-beta precursor protein (APP). TMEM30A physically interacts with betaCTF in endosomes and may impair vesicular traffic, leading to abnormally enlarged endosomes. Data suggested that TMEM30A is involved in betaCTF-dependent endosome abnormalities that are related to Abeta overproduction

Mouse (Murine) Amyloid beta (Abeta) interaction partners

  1. data indicate that Drp1 is a direct target of Cdk5, and Cdk5-mediated phosphorylation of Drp1 at Serine 579 regulates Abeta1-42 induced mitochondrial fission and neuronal toxicity.

  2. miR98 reduced the production of Abeta and improved oxidative stress and mitochondrial dysfunction through activation of the Notch signaling pathway by binding to HEY2 in Alzheimer's disease mice.

  3. Heme and Hb suppress immune activity of primary mouse astrocytes by reducing expression of several proinflammatory cytokines (e.g. RANTES (regulated on activation normal T cell expressed and secreted)) and the scavenger receptor CD36 and reducing internalization of Abeta(1-42) by astrocytes.

  4. extracellular cholesterol concentration in serum under conditions of Npc1 deficiency can influence intracellular cholesterol content/distribution and lysosomal efficacy, triggering the accumulation of toxic APP-cleaved products, eventually leading to cell death.

  5. Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease.

  6. This study provides a novel mechanism underlying aggregation of Abeta peptides via BC1 induction of APP mRNA translation.

  7. This study uncovered two clear phases in the life of APP23 mice: developmental and aging. Development displays similarities to young carriers of familial Alzheimer's disease (AD) mutations. All gene expression differences between APP23 and control mice correlate with aging. Age-related expression changes appear exacerbated/accelerated in APP23 mice.

  8. These results provide evidence for an emerging role of BAG-1M in the regulation of BACE1 expression and AD pathogenesis and that targeting the BAG-1M-NF-kappaB complex may provide a mechanism for inhibiting Abeta production and plaque formation.

  9. Conformational changes in a mouse model of Alzheimer's disease-linked amyloid beta and APP take place before the amyloids plaques can be seen.

  10. These results support the proposition that Aβ release during thrombosis serves as part of a natural defense against infection.

  11. These data suggest a novel regulatory function of juxta- and intra-membrane domains on the metabolism and function of APP.

  12. Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice.

  13. pharmacological inhibition of PARP-1 reversed both particulate matter-induced Abeta increase and glial activation.

  14. The concentrations of Abeta (1-42) were also significantly higher in early stage Alzheimer's disease (AD) mice compared with WT mice, however, the levels were markedly lower compared with later stage AD mice, as determined by ELISA. In addition to increased levels of Abeta (1-42) in mice with later stage AD, reduced astrocyte staining was observed compared with WT mice.

  15. work expands the current knowledge regarding Abeta seeding and the consequences thereof and attributes microglia an important role in diminishing Abeta seeding by environmental enrichment.

  16. This study demonstrated that APP as a novel receptor for Slit ligand mediating axon guidance and neural circuit formation.

  17. In vivo, the NHE6 knockout (NHE6(KO)) mouse model showed elevated Abeta in the brain, consistent with a causal effect. Increased nuclear translocation of histone deacetylase 4 (HDAC4) in ApoE4 astrocytes, compared with the nonpathogenic ApoE3 allele, suggested a mechanistic basis for transcriptional down-regulation of NHE6.

  18. This commentary reviews the role of the Alzheimer amyloid peptide Abeta on basal synaptic transmission, synaptic short-term plasticity, as well as short- and long-term potentiation in transgenic mice, with a special focus on N-terminal truncated Abeta4-42.

  19. ADAP KO mice developed glomerular pathology. ADAP KO podocytes lack cell protrusions with actin cytoskeleton forming circumferential stress fibers.

  20. Therefore, APP modulates Nav1.6 sodium channels through a Go-coupled JNK pathway, which is dependent on phosphorylation of APP at Thr668.

beta Amyloid (Abeta) Antigen Profile

Protein Summary

This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.

Gene names and symbols associated with anti-Amyloid beta (Abeta) Antibodies

  • amyloid beta precursor protein (APP) antibody
  • amyloid beta precursor protein (app) antibody
  • amyloid beta precursor protein (App) antibody
  • amyloid beta (A4) precursor protein (App) antibody
  • aaa antibody
  • Abeta antibody
  • Abpp antibody
  • ad1 antibody
  • Adap antibody
  • Ag antibody
  • appi antibody
  • betaApp antibody
  • ctfgamma antibody
  • Cvap antibody
  • E030013M08Rik antibody
  • PN-II antibody
  • pn2 antibody

Protein level used designations for anti-Amyloid beta (Abeta) Antibodies

alzheimer disease amyloid protein , amyloid beta A4 protein , beta-amyloid peptide , cerebral vascular amyloid peptide , peptidase nexin-II , preA4 , protease nexin-II , amyloid beta (A4) precursor protein (peptidase nexin-2, Alzheimer disease) , amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) , beta-amyloid precursor protein , alzheimer disease amyloid A4 protein homolog , amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) , ABPP , AG , amyloid A4 , amyloidogenic glycoprotein , appican , protease nexin II

351 Homo sapiens
448208 Xenopus (Silurana) tropicalis
100427716 Macaca mulatta
54226 Rattus norvegicus
11820 Mus musculus
Selected quality suppliers for anti-beta Amyloid (Abeta) Antibodies
Did you look for something else?